• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Memorial Sloan Kettering, Cota Partner to Advance Personalized Cancer Treatment

by HITC Staff 11/09/2017 Leave a Comment

Memorial Sloan Kettering Cancer Center

In 2011, Cota, a healthcare data and analytics company bridging precision medicine and population health, was founded by doctors for doctors. Over the past six years, the start-up has moved beyond precision medicine as a goal to a reality, and just this past year, have secured a multi-year collaboration with Novartis towards breast cancer and recruited top thought leaders in the space, like former Deputy Chief Health Officer at IBM Watson, Dr. Andrew Norden.

Today, Cota announced their latest collaboration with Memorial Sloan Kettering Cancer Center (MSK) on a multi-year commitment. MSK is entrusting Cota with all of its clinical and genomic data to fuel how cancer care is delivered by feeding MSK’s data sets through the Cota Nodal Address (CNA). The CNA categorizes patient factors, their diseases and intended therapies by creating cohorts of similar patients. This process will bring MSK one step closer to personalized medicine by identifying care pathways and informing how physicians perform day-to-day care. This collaboration will also strengthen Cota’s real-world evidence database and further validate the CNA.

MSK and Cota will also form a technology collaboration focused on advanced analytics to enable more consistent disease classification within oncology, which could help drive further insights for both researchers and physicians.

“Memorial Sloan Kettering doctors and researchers are constantly innovating in an effort to provide the best care to our patients, but some of that rich experience and knowledge is obscured in individual patients’ clinical records,” said Paul Sabbatini, M.D., deputy physician-in-chief for clinical research at Memorial Sloan Kettering in a statement. “Working with Cota, which has a unique approach to transforming clinical data such as ours, will help us have a more robust understanding of the components that make up a patient’s diagnosis and care pathway. This organized and analyzed data will help our physicians practice more efficiently, optimizing the care a patient receives based on a variety of characteristics and ultimately can improve outcomes for all cancer patients as this knowledge is shared.”

 

Tagged With: COTA, Cota Healthcare, Personalized Cancer Medicine

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |